Patients Discontinuing Slimming Medications Put On Weight at a Quadrupled Rate Than Dieters

New research indicates that individuals who stop using new slimming jabs like Mounjaro or Wegovy may regain lost weight much more quickly than those who stop traditional lifestyle regimens.

Research printed in a leading health publication points out that while obese individuals often shed a large proportion of their body weight while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.

"Users buying such treatments need to be cognizant of the potential of quick rebound weight gain when the medication is stopped," stated lead investigator Dr. Susan Jebb.

That rate of regain implies a reversion to starting weight in about one and a half years.

Comparing Treatments

The research, which reviewed 37 of trials involving thousands of patients, compared the outcomes of these new drugs with conventional dieting.

The team emphasize that people who lose weight through diet and exercise typically see a more gradual weight regain—around 100 grams monthly—once they finish.

Explaining the Quick Rebound

Experts suggest the way of the drugs accounts for the heightened weight return.

GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.

"Sustained high doses of GLP-1 concentrations far above than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and could diminish sensitivity to its effects," said Dr. Adam Collins, a dietetics researcher.

"Stopping of this medication leads to hunger is no longer kept in check, making overeating much more probable."

A Chronic Condition?

Medical guidelines advise the injections for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.

A number of clinicians argue that, given the significant potential of relapse, the therapy might need to be long-term.

This view is reinforced by drug manufacturers, who state that the findings "emphasize the persistent nature of obesity," comparing it to managing diseases like hypertension.

User Experiences

People who have discontinued the jabs describe a sudden resurgence of appetite.

"It was like a switch activating and you become ravenous," recalled a patient.

This difficulty is exacerbated if individuals have not established permanent dietary or behavioural changes during therapy.

Widespread Adoption

Figures indicate that millions of adults in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.

• Adoption is greater among females compared to men.
• The middle-aged age group shows the highest usage rates.
• Many obtain the medications through private prescriptions rather than the NHS.

In conclusion, researchers caution that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent fix and long-term success hinges on integrated behavioural support.